Written by the Nuvirox Research Team
Key Points
- Nicotinamide riboside has been shown to both prevent and reverse paclitaxel-induced peripheral neuropathy in rodent studies — a meaningfully strong result in animal research.
- A VA-funded research program is now extending this work to cisplatin, a different chemotherapy drug, and to related side effects including dry eye and hearing loss.
- A registered human clinical trial (NCT04112641) exists for chemotherapy-induced peripheral neuropathy, though completed results were not available in current search results.
Short answer: rodent research shows real, consistent promise for preventing and reversing chemotherapy-induced nerve damage, and human trials are already in motion — but as of this writing, we could not confirm any completed human results. That gap between promising animal data and confirmed human benefit is worth sitting with rather than glossing past.
What chemotherapy-induced peripheral neuropathy is
Chemotherapy-induced peripheral neuropathy (CIPN) is nerve damage — causing numbness, tingling, pain, and loss of proprioception (position sense) — that develops as a side effect of certain chemotherapy drugs, particularly platinum-based compounds like cisplatin and taxanes like paclitaxel. It's a common and often disabling complication for cancer patients and survivors, and currently has no universally effective evidence-based treatment, which is part of why this research area has drawn sustained attention from multiple independent research groups over time. CIPN can also be dose-limiting, meaning it sometimes forces oncologists to reduce chemotherapy doses or discontinue treatment earlier than planned, which makes finding an effective preventive or reversing strategy relevant not just to a patient's day-to-day comfort but potentially to their broader cancer treatment course as well.
What the rodent research actually found
A research laboratory investigating this question demonstrated that nicotinamide riboside could both prevent and reverse paclitaxel-induced peripheral neuropathy in rodent models — a notably strong claim, since "reversing" existing nerve damage is a higher bar than simply preventing it. This distinction matters clinically: a prevention-only effect would mean NR needs to be started before or during chemotherapy to have value, while a reversal effect suggests potential relevance even for patients who already have established neuropathy from treatment they've already completed. Related work from the same group found NR also alleviated corneal and body hypersensitivity from paclitaxel, described in our companion article on NAD+ and dry eye syndrome.
Study snapshot
| Established finding | NR prevents and reverses paclitaxel-induced neuropathy (rodents) |
| Current extension | Testing cisplatin-induced neuropathy, dry eye, and hearing loss (VA-funded, rodents) |
| Registered human trial | NCT04112641 — chemotherapy-induced peripheral neuropathy |
| Completed human results | Not confirmed in current search results |
Why this research program stands out
What makes this body of work more developed than some other topics in this batch is the clear translational pathway: a specific drug (paclitaxel), a specific side effect (neuropathy), a demonstrated rodent effect (both prevention and reversal), an active extension to a second chemotherapy drug (cisplatin) and additional side effects (dry eye, hearing loss), and a registered human trial identifier. That's a more complete research pipeline than most conditions covered in this batch have — even though, importantly, we could not verify published, completed human efficacy results as of this writing.
What this doesn't establish yet
Rodent studies, even strong ones, don't guarantee the same magnitude of effect in humans, and CIPN's severity and pattern can vary considerably by chemotherapy regimen, cumulative dose, and individual patient factors that a rodent model can't fully replicate. Until human trial results are published and reviewed, any claim of proven human benefit would be running ahead of the evidence. It's also worth noting that CIPN prevention and CIPN reversal may not necessarily share the same underlying requirements — a treatment that works well started early, before nerve damage accumulates, isn't guaranteed to work equally well once damage is already established, even if rodent data suggests both effects are possible; human trials will need to clarify this distinction with real patient timelines and treatment histories.
What this means if you're facing chemotherapy or living with CIPN
If you're scheduled for chemotherapy known to carry neuropathy risk, or you're currently managing CIPN, this is genuinely worth raising with your oncology team — both because of the active research (including potential trial eligibility) and because CIPN management already has some established approaches (dose adjustments, certain medications) your oncologist can walk through based on your specific chemotherapy regimen and treatment goals. This isn't a situation to navigate with a supplement alone, given how much individual variation exists in both cancer treatment plans and neuropathy presentation. For related nerve-related NAD+ research, see our review of NAD+ and diabetic neuropathy, a different but mechanistically related nerve condition with its own separate trial history.
FROM NUVIROX
Because of the caveats above, we'd encourage you to read this as general background rather than a treatment plan. If you're curious about the ingredient at the center of this research, here's what's in ours, alongside clinician-routing guidance for anything beyond everyday support:
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol + 50 mg quercetin — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg fenugreek galactomannans to support absorption
- Backed by a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
Frequently asked questions
Can NAD+ supplements prevent chemotherapy-related nerve damage?
Rodent studies show promise for both prevention and reversal of paclitaxel-induced neuropathy specifically. We could not confirm completed human trial results, so this isn't yet an established human benefit.
Is there a human trial I could look into?
Yes, one is registered under identifier NCT04112641. Eligibility and current status are best explored with your oncology team, given how individualized cancer treatment and trial participation decisions are.
Does this work for all types of chemotherapy?
The strongest rodent evidence is specifically for paclitaxel; research is actively extending to cisplatin, a different drug class, but results for cisplatin-related neuropathy were not confirmed as completed in current search results.
Should I take an NAD+ supplement during chemotherapy without telling my oncologist?
No — any supplement during active cancer treatment should be discussed with your oncology team first, given the potential for interactions with chemotherapy drugs and their metabolism.
Does CIPN always go away after chemotherapy ends?
Not always — CIPN can persist for months or years after treatment ends in some patients, and for a subset it becomes a long-term or permanent condition, which is part of why finding an effective preventive or reversing strategy carries real significance beyond short-term symptom relief.
Are there current treatments for CIPN while we wait for this research to mature?
Management approaches vary by severity and may include dose adjustments, certain medications for nerve pain, and physical therapy — your oncology team can walk through what's appropriate for your specific situation, chemotherapy regimen, and overall treatment goals.
The bottom line: this is one of the more actively developing research threads in this entire batch — real rodent efficacy data, a clear extension plan, and a registered human trial — and also a clear reminder that "clear translational pathway" and "confirmed human result" are still two different things.
References
- Nicotinamide Riboside for the Treatment of Chemotherapy-Induced Neuropathy, Dry Eye Syndrome, and Hearing Loss. VA-funded research grant, I21-RX003464-01A1.
- Hamity MV, et al. Nicotinamide Riboside Alleviates Corneal and Somatic Hypersensitivity Induced by Paclitaxel in Male Rats. Invest Ophthalmol Vis Sci (IOVS/ARVO).
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.